KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Non-cash Items (2016 - 2025)

Ionis Pharmaceuticals has reported Non-cash Items over the past 14 years, most recently at $5.7 million for Q4 2025.

  • Quarterly results put Non-cash Items at $5.7 million for Q4 2025, up 2750.0% from a year ago — trailing twelve months through Dec 2025 was $5.7 million (up 2750.0% YoY), and the annual figure for FY2025 was $5.7 million, up 2750.0%.
  • Non-cash Items for Q4 2025 was $5.7 million at Ionis Pharmaceuticals, down from $37.2 million in the prior quarter.
  • Over the last five years, Non-cash Items for IONS hit a ceiling of $101.8 million in Q1 2021 and a floor of $200000.0 in Q4 2024.
  • Median Non-cash Items over the past 5 years was $51.4 million (2022), compared with a mean of $49.2 million.
  • Biggest five-year swings in Non-cash Items: soared 4475.0% in 2023 and later plummeted 99.45% in 2024.
  • Ionis Pharmaceuticals' Non-cash Items stood at $49.6 million in 2021, then plummeted by 98.39% to $800000.0 in 2022, then soared by 4475.0% to $36.6 million in 2023, then plummeted by 99.45% to $200000.0 in 2024, then surged by 2750.0% to $5.7 million in 2025.
  • The last three reported values for Non-cash Items were $5.7 million (Q4 2025), $37.2 million (Q3 2025), and $42.3 million (Q2 2025) per Business Quant data.